Core Insights - Novo Nordisk reported a robust sales figure of 309.1 billion Danish Krone for 2025, reflecting a 10% year-on-year growth at constant exchange rates, driven primarily by the strong performance of its semaglutide product line, which accounted for over 70% of total sales [1] - The company is focusing on deepening its core therapeutic areas, expanding its research pipeline, and enhancing localization strategies to maintain its industry-leading position and drive long-term growth [1] Group 1: Product Development and Innovation - The oral formulation of Wegovy® (25mg) received FDA approval in December 2025, marking it as the first oral GLP-1 product for weight management, with a total weekly prescription volume reaching approximately 50,000 since its launch [2] - The 7.2mg dose of semaglutide injection has received positive opinions from the EMA and has been approved in the UK, with a supplemental new drug application submitted to the FDA, showing an average weight reduction of 21% in the STEP UP trial [2] - CagriSema, a next-generation candidate in the metabolic field, has shown promising results in the REDEFINE 1 trial, achieving a weight loss of 22.7% over 68 weeks, with a new drug application submitted to the FDA in December 2025 [3] Group 2: Clinical Trials and Collaborations - The REIMAGINE 2 global Phase 3 clinical trial results demonstrated that CagriSema outperformed semaglutide in reducing HbA1c and weight, validating the synergistic potential of the "GLP-1 + insulin" dual pathway therapy [4] - The company is collaborating with Aspect Biosystems to develop advanced cell therapies for diabetes, exploring new pathways for diabetes treatment [4] - Novo Nordisk acquired Akero Therapeutics to enter the non-alcoholic steatohepatitis (NASH) treatment space, which aligns closely with its core business and presents significant market potential [4] Group 3: Market Expansion and Localization - The company is focusing on deepening its presence in the Greater China market through a comprehensive industry chain layout and innovative business models, establishing a "three-engine" synergy of production, research, and commercial operations [4] - In 2025, Novo Nordisk established an open innovation center in China to enhance innovation and collaboration levels, driving synergistic innovation across its three engines [4] - The company is actively building a digital health ecosystem in collaboration with major domestic health platforms to improve accessibility and service depth in obesity prevention and management [5] Group 4: Product Approvals and Market Impact - Novo Nordisk's weight management drug, Novoing® (Nangoglutide), received approval for cardiovascular indications, becoming the first weight management drug in China with evidence for both weight loss and cardiovascular protection [6] - The core product, Novotai® (IcoSema), has expanded its indications to include type 2 diabetes, cardiovascular diseases, and chronic kidney disease, with ongoing efforts to broaden its therapeutic applications [6] - The global innovative drug IcoSema's application has been submitted to the NMPA, aiming to benefit Chinese patients with type 2 diabetes [6]